Korean J Dermatol.  2012 Jun;50(6):491-496.

Evaluation of Efficacy and Skin Irritation during Treatment of Nadifloxacin 1% Cream in Acne Vulgaris Patient

Affiliations
  • 1Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea. karrot75@hanmail.net
  • 2Sinsa Theme Dermatologic Clinic, Seoul, Korea.

Abstract

BACKGROUND
Nadifloxacin is a synthetic fluoroquinolone with a broad spectrum. It has been suggested to not only have antibacterial, but also anti-inflammatory actions. In addition, it is effective against antibiotic-resistant Propionibacterium acne. Upon review of the literature, however, no studies have been performed concerning the efficacy and safety in terms of irritation potential and skin barrier changes after applying nadifloxacin.
OBJECTIVE
This study intended to evaluate the skin irritation and changes of the skin barrier function associated with the administration of nadifloxacin 1% cream for the treatment of acne vulgaris. Furthermore, the efficacy and safety of nadifloxacin 1% cream were also assessed.
METHODS
The changes in the lesion counts, Korean Acne Grading System (KAGS) and adverse events were recorded. The biophysical profiles of the skin, including transepidermal water loss (TEWL), skin surface hydration and redness were measured by Tewameter(R), Corneometer(R) and Mexameter(R) for 3 weeks.
RESULTS
At the end of the therapy, 69% of inflammatory lesions (p<0.0001) and 27% of noninflammatory lesions (p=0.26) resulting from acne were decreased from the baseline. Adverse events were reported in two patients, but they were transient and tolerable. The skin barrier function showed no changes during the treatment periods.
CONCLUSION
Nadifloxacin 1% cream is effective for the treatment of acne vulgaris without the changes of skin barrier function.

Keyword

Acne; Nadifloxacin; Skin barrier

MeSH Terms

Acne Vulgaris
Fluoroquinolones
Humans
Propionibacterium
Quinolizines
Skin
Fluoroquinolones
Quinolizines
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr